InnoPharmax Inc.
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and… Read more
InnoPharmax Inc. (4172) - Total Liabilities
Latest total liabilities as of June 2025: NT$42.89 Million TWD
Based on the latest financial reports, InnoPharmax Inc. (4172) has total liabilities worth NT$42.89 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
InnoPharmax Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how InnoPharmax Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
InnoPharmax Inc. Competitors by Total Liabilities
The table below lists competitors of InnoPharmax Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trisul S.A
SA:TRIS3
|
Brazil | R$1.88 Billion |
|
Innoprise Plantations Bhd
KLSE:6262
|
Malaysia | RM98.25 Million |
|
GiG Software p.l.c.
F:K0W
|
Germany | €18.80 Million |
|
Intiland Development Tbk
JK:DILD
|
Indonesia | Rp6.75 Trillion |
|
U-Tech Media Corp
TW:3050
|
Taiwan | NT$2.62 Billion |
|
Neousys Technology Inc.
TWO:6922
|
Taiwan | NT$1.02 Billion |
|
Evergreen Corp
NASDAQ:EVGR
|
USA | $11.69 Million |
|
Nan Yang Dyeing & Finishing Co Ltd
TW:1410
|
Taiwan | NT$211.41 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down InnoPharmax Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InnoPharmax Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InnoPharmax Inc. (2019–2024)
The table below shows the annual total liabilities of InnoPharmax Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$30.21 Million | -37.89% |
| 2023-12-31 | NT$48.65 Million | -16.56% |
| 2022-12-31 | NT$58.31 Million | +136.90% |
| 2021-12-31 | NT$24.61 Million | -88.20% |
| 2020-12-31 | NT$208.61 Million | +156.13% |
| 2019-12-31 | NT$81.44 Million | -- |